Significance of neoadjuvant chemotherapy in the treatment of limited-disease small cell lung cancer_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

SHAO Weipeng , HUANG Jingjing , FENG Hongxiang , SHAO Xueqi , WANG Xiaowei , ZHANG Zhenrong ,  LIU Deruo

Department of Thoracic Surgery, China-Japan Friendship Hospital, Peking University China-Japan Friendship School of Clinical Medicine, Beijing, 100029, P.R.China;

Corresponding author：

LIU Deruo, Email: deruoliu@vip.sina.com

Keywords：

Small cell lung cancer; surgery; neoadjuvant chemotherapy

DOI：

10.7507/1007-4848.201808022

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the significance of neoadjuvant chemotherapy in the treatment of limited-disease small cell lung cancer (LD-SCLC). Methods We retrospectively analyzed the clinical data of 55 LD-SCLC patients who underwent surgery in the Department of Thoracic Surgery, China-Japan Friendship Hospital from May 2007 to August 2016. There were 42 males and 13 females with a mean age of 57 years. All patients underwent clinical staging before treatment. According to the different treatments, the patients were divided into two groups, a preoperative neoadjuvant chemotherapy group and a direct surgery group. The comparison of long-term survival rates was made between the two groups. Results Among the 55 patients, median survival time was 27 months. The 1-, 3-, 5-year survival rate was 89.1%, 45.0%, 33.8% respectively. Treatment methods and clinical N stage were significantly different in prognosis (P<0. 05). The results of Cox proportional hazards regression model showed that clinical N stage was prognostic factor of LD-SCLC patients (P<0. 05). Conclusion Patients with clinical stage Ⅰ and Ⅱ SCLC are better to receive direct surgery. For patients with clinical stage Ⅲ, it is recommended to reach partial response or complete response with neoadjuvant chemotherapy before surgery. The status of lymph node metastasis is closely related to survival, thus identifying the accurate clinical stage is crucial before treatment.

Citation： SHAO Weipeng, HUANG Jingjing, FENG Hongxiang, SHAO Xueqi, WANG Xiaowei, ZHANG Zhenrong, LIU Deruo. Significance of neoadjuvant chemotherapy in the treatment of limited-disease small cell lung cancer. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2019, 26(5): 419-424. doi: 10.7507/1007-4848.201808022 Copy

1.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
2.	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30.
3.	Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer, 2012, 131(5): 1210-1219.
4.	Schreiber D, Rineer J, Weedon J, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated. Cancer, 2010, 116(5): 1350-1357.
5.	Combs SE, Hancock JG, Boffa DJ, et al. Bolstering the case for lobectomy in stages Ⅰ, Ⅱ, and ⅢA small-cell lung cancer using the National Cancer Data Base. J Thorac Oncol, 2015, 10(2): 316-323.
6.	Fujimori K, Yokoyama A, Kurita Y, et al. A pilot phase 2 study of surgical treatment after induction chemotherapy for resectable stage Ⅰ to ⅢA small cell lung cancer. Chest, 1997, 111(4): 1089-1093.
7.	Hara N, Ohta M, Ichinose Y, et al. Influence of surgical resection before and after chemotherapy on survival in small cell lung cancer. J Surg Oncol, 1991, 47(1): 53-61.
8.	Wada H, Yokomise H, Tanaka F, et al. Surgical treatment of small cell carcinoma of the lung: advantage of preoperative chemotherapy. Lung Cancer, 1995, 13(1): 45-56.
9.	Veronesi G, Scanagatta P, Leo F, et al. Adjuvant surgery after carboplatin and VP16 in resectable small cell lung cancer. J Thorac Oncol, 2007, 2(2): 131-134.
10.	Ohkubo T, Ito K, Sugiura H, et al. Surgical analysis for small cell lung cancer of the lung. Kyobu Geka, 1999, 52(13): 1061-1066.
11.	Lucchi M, Mussi A, Chella A, et al. Surgery in the management of small cell lung cancer. Eur J Cardiothorac Surg, 1997, 12(5): 689-693.
12.	Jin F, Qu B, Fu Z, et al. Prognostic value of metabolic parameters of metastatic lymph nodes on (18)F-FDG PET/CT in patients with limited-stage small-cell lung cancer with lymph node involvement. Clin Lung Cancer, 2018, 19: e101-e108.
13.	Nakamura H, Kato Y, Kato H. Outcome of surgery for small cell lung cancer--response to induction chemotherapy predicts survival. Thorac Cardiovasc Surg, 2004, 52(4): 206-210.
14.	Friess GG, McCracken JD, Troxell ML, et al. Effect of initial resection of small-cell carcinoma of the lung: a review of Southwest Oncology Group Study 7628. J Clin Oncol, 1985, 3(7): 964-968.
15.	段勇, 白连启, 龚昌帆, 等. 术前化疗对小细胞肺癌远期生存的影响. 中华医学杂志, 2009, 89(31): 2199-2201.

1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30.
3. Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer, 2012, 131(5): 1210-1219.
4. Schreiber D, Rineer J, Weedon J, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated. Cancer, 2010, 116(5): 1350-1357.
5. Combs SE, Hancock JG, Boffa DJ, et al. Bolstering the case for lobectomy in stages Ⅰ, Ⅱ, and ⅢA small-cell lung cancer using the National Cancer Data Base. J Thorac Oncol, 2015, 10(2): 316-323.
6. Fujimori K, Yokoyama A, Kurita Y, et al. A pilot phase 2 study of surgical treatment after induction chemotherapy for resectable stage Ⅰ to ⅢA small cell lung cancer. Chest, 1997, 111(4): 1089-1093.
7. Hara N, Ohta M, Ichinose Y, et al. Influence of surgical resection before and after chemotherapy on survival in small cell lung cancer. J Surg Oncol, 1991, 47(1): 53-61.
8. Wada H, Yokomise H, Tanaka F, et al. Surgical treatment of small cell carcinoma of the lung: advantage of preoperative chemotherapy. Lung Cancer, 1995, 13(1): 45-56.
9. Veronesi G, Scanagatta P, Leo F, et al. Adjuvant surgery after carboplatin and VP16 in resectable small cell lung cancer. J Thorac Oncol, 2007, 2(2): 131-134.
10. Ohkubo T, Ito K, Sugiura H, et al. Surgical analysis for small cell lung cancer of the lung. Kyobu Geka, 1999, 52(13): 1061-1066.
11. Lucchi M, Mussi A, Chella A, et al. Surgery in the management of small cell lung cancer. Eur J Cardiothorac Surg, 1997, 12(5): 689-693.
12. Jin F, Qu B, Fu Z, et al. Prognostic value of metabolic parameters of metastatic lymph nodes on (18)F-FDG PET/CT in patients with limited-stage small-cell lung cancer with lymph node involvement. Clin Lung Cancer, 2018, 19: e101-e108.
13. Nakamura H, Kato Y, Kato H. Outcome of surgery for small cell lung cancer--response to induction chemotherapy predicts survival. Thorac Cardiovasc Surg, 2004, 52(4): 206-210.
14. Friess GG, McCracken JD, Troxell ML, et al. Effect of initial resection of small-cell carcinoma of the lung: a review of Southwest Oncology Group Study 7628. J Clin Oncol, 1985, 3(7): 964-968.
15. 段勇, 白连启, 龚昌帆, 等. 术前化疗对小细胞肺癌远期生存的影响. 中华医学杂志, 2009, 89(31): 2199-2201.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Significance of neoadjuvant chemotherapy in the treatment of limited-disease small cell lung cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content